> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-25/
- Published: 2020-08-23T12:00:00.000Z
- Updated: 2026-09-14T16:26:05.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140899

**Medeon Biodesign** has agreed to sell to Tokyo-based **Terumo Corp.** its large bore vascular closure system. The transaction includes an up-front payment of $20 million and future milestone payments. The acquired device, a suture-mediated closure device with two braids, is intended to target percutaneous large bore procedures via the common femoral artery. It is designed to achieve rapid and reliable hemostasis at the puncture sites with excellent clinical outcomes, Terumo says.

**Boston Scientific** has acquired **EMcision, Ltd.**, a privately held company located in the U.K. The acquisition will expand Boston Scientific’s endoscopy portfolio to include the Habib EndoHPB probe, an endoscopic bipolar radiofrequency device used to coagulate tissue in the gastrointestinal tract.

**Cipher Pharmaceuticals** has acquired the exclusive Canadian rights to right to develop and market Trulance (plecanatide) from **Synergy Pharmaceuticals**. The once-daily tablet is approved by FDA for treating adults with chronic idiopathic constipation and irritable bowel syndrome with constipation.